

**REGISTERED COMPANY NUMBER: 07564771 (England and Wales)**  
**REGISTERED CHARITY NUMBER: 1141583**

**GENE PEOPLE**

**Unaudited Financial Statements for the Year Ended 31 March 2023**

Tudor John Limited  
Nightingale House  
46-48 East Street  
Epsom  
Surrey  
KT17 1HQ

# **GENE PEOPLE**

## **Contents of the Financial Statements for the year ended 31 March 2023**

	<b>Page</b>
<b>Reference and Administrative Details</b>	<b>1</b>
<b>Report of the Trustees</b>	<b>2 to 6</b>
<b>Independent Examiner's Report</b>	<b>7</b>
<b>Statement of Financial Activities</b>	<b>8</b>
<b>Balance Sheet</b>	<b>9</b>
<b>Notes to the Financial Statements</b>	<b>10 to 16</b>
<b>Detailed Statement of Financial Activities</b>	<b>17</b>

## **GENE PEOPLE**

### **Reference and Administrative Details for the year ended 31 March 2023**

<b>TRUSTEES</b>	Ms R L Frankel (resigned 21.12.22) Dr C Ruff S Mitra A J Kent Ms E Fernandez-Gonzalez (resigned 15.8.22) D Ansel C J Conway Dr N V Taverner D G Atkins Ms A Patel (appointed 24.6.23)
<b>REGISTERED OFFICE</b>	Nightingale House 46-48 East Street Epsom Surrey KT17 1HQ
<b>REGISTERED COMPANY NUMBER</b>	07564771 (England and Wales)
<b>REGISTERED CHARITY NUMBER</b>	1141583
<b>INDEPENDENT EXAMINER</b>	Tudor John Limited Nightingale House 46-48 East Street Epsom Surrey KT17 1HQ
<b>SOLICITORS</b>	Stone King LLP, Boundary House, 91 Charterhouse Street, Barbican, London, EC1M 6HR
<b>BANKERS</b>	Barclays Corporate, Level 27, 1 Churchill Place, London, E14 5HP

**Report of the Trustees  
for the year ended 31 March 2023**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

**Welcome from the Chair**

2022-23 has been a challenging year for Gene People and the community of patients and families living with rare genetic conditions we serve and support. Emerging from the pandemic to face a cost-of-living crisis and a NHS struggling to deal with a huge backlog of patients awaiting treatment put huge pressure on the charity, but I am proud to say that our team rose to the challenge. I commend their dedication and expertise.

Our unique genetic counsellor led helpline supported over 150 families with complex needs, who were struggling to get a diagnosis, understand what it means and find the help they needed from the NHS or other statutory agencies, and the professionals supporting them. Feedback from callers shows just how valuable the help we provide is.

Our Partnership Network continues to grow and counts over 140 support groups as members. We have laid on a range of events and activities designed to enable them to build their ability and capacity to support patients and families, culminating in a hugely successful Symposium last Autumn - an event we will repeat in 2023.

Elsewhere our reach continues to extend. We are collaborating with the ABPI, the BIA, LifeArc and a range of other bodies. We have contributed thoughtful and well received inputs to consultations by Government, the NHS and other bodies, demonstrating Gene People's impact and the importance of the message we send - "speaking truth to power" - to those making policy and delivering care and support to those in need.

We receive no government funding. We rely on the generosity of donors to continue to provide vital support to patients and families, and I am grateful to everyone who has helped us. Thank you all!

Alastair Kent OBE FRSA  
Chair of Trustees

**OBJECTIVES AND ACTIVITIES**

**Objectives and aims**

Gene People has a vision to improve the lives of those affected by a genetic condition through the provision of resources and support both to individuals and families, and to the hundreds of condition-specific charities and patient groups that have been established in the UK.

The objectives of the charity are:

- To raise awareness and advance the education of the public on the subject of genetic disorders
- The relief of persons suffering from genetic disorders
- The advancement of medical research into the causes, cure, prevention or relief of such disorders and the publication of results of that research
- To promote the efficiency and effectiveness of other genetic disorder charities so they may achieve their charitable purposes.

**Report of the Trustees  
for the year ended 31 March 2023**

**OBJECTIVES AND ACTIVITIES**

**Significant activities**

A key activity for 2022-23 was creating and publishing our new Strategy. This is available on our website to download on this page: <https://genepeople.org.uk/about-us/gene-people-strategy-2022-2025/>

Everything Gene People does now falls into three strategic pillars, all of which have been designed to improve the lives of those living with genetic conditions. The three pillars are:

- Support and Information
- Strengthening condition-specific support groups and organisations
- Advocacy and collaboration.

The Trustees had set some specific plans for 2022-23. These were:

- *Develop and implement a UK-wide marketing strategy for the Helpline, particularly through social media:* we piloted some advertisements on social media, which, sadly, prompted a substantial amount of 'trolling' to the degree that this activity was stopped. We have yet to secure sufficient funding to undertake the UK-wide marketing we would like for the Helpline.
- *Launch the Helpline translation service to the public:* we have regularly posted messages in languages other than English to notify people that we have a translation service available. We are grateful to LanguageLine for being our translation partner.
- *Publish refreshed Directory of Condition-Specific Groups and Organisations:* due to staff capacity this is currently on pause.
- *Hold regular webinars on a range of topics for the Partnership Network:* monthly webinars on a host of topics were held for the Partnership Network. Topics included practical items like data protection, communications and fundraising. We are very grateful to the BIA RDIG for their sponsorship of this series during the year.
- *Hold the Gene People Leadership Symposium:* the first Symposium since 2018 was held online on two separate half-days. It included the first ever Gene People Awards. Feedback was overwhelmingly positive with an audience spanning each part of the genetic conditions' ecosystem from condition-specific support groups to NHS genetic counsellors to the medicines industry. This would not have been possible without the kind support from The Adelphi Genetics Forum, Ipsen, Global Blood Therapeutics and PTC Therapeutics.
- *Launch the Gene People Partnership Network Advisory Panel:* this has been created and includes small to medium sized organisations, all bringing their own perspective on the work of Gene People.
- *Submit responses to consultations with input from our Partnership Network where possible:* all the Gene People submissions can be seen on this page on our website: <https://genepeople.org.uk/about-us/national-policy/> We are particularly proud of the collaboration with sister charities, industry partners and NHS colleagues in response to the Mental Health and Wellbeing Plan, which stimulated additional conversations with policy makers.
- *Continue recruitment to the Gene People Corporate Connection and develop its programme of work:* we are grateful to the first members of the Corporate Connection, Ipsen and PTC Therapeutics.

We represent the views of our community at events, and are a member of a range of organisations including:

- Association of the British Pharmaceutical Industry Patient Organisation Forum
- Breaking Down Barriers
- NIHR Genetics NSG Clinical Reference Network
- Disabled Children's Partnership
- Genetic Alliance UK
- Steering Group of Pharma Insight Group
- Prescription Charges Coalition
- Specialised Health Care Alliance.

"Honestly you've been so helpful, more than any other doctor or optician I've spoken to" – Helpline enquirer

The team have actively contributed to events and meetings organised by these groups as speaker, chair or facilitator. In addition, Gene People has engaged actively with:

- Association of Genetic Nurses and Counsellors
- British Society for Genetic Medicine
- European Rare Disease Helpline Network
- GOSH
- Manchester University

**Report of the Trustees  
for the year ended 31 March 2023**

**OBJECTIVES AND ACTIVITIES**

- Nuffield Council on Bioethics
- Public Policy Projects
- Rare Bone Disease Summit
- Roald Dahl Marvellous Children's Charity
- Westminster Health Forum.

These activities took place alongside the core business of the Helpline, fundraising and running the charity. All of this work is not possible without the kind support of generous donors and funders. While the fundraising environment is challenging, Gene People is delighted to have been supported in 2022-23 by:

- Adelphi Genetics Forum
- Amicus Therapeutics
- Arnold Clark
- Edward Gostling Foundation
- GiveAsYouLive givers
- Global Blood Therapeutics
- Ipsen
- London Marathon Runners
- PTC Therapeutics
- Regular givers
- UK Bio Industry Association Rare Disease Industry Group
- And all those who prefer to remain anonymous.

"I appreciated the speed of response and the offer of a phone call to discuss my concerns. I really didn't know what to do or who to turn to and am so grateful that this service was available. A real lifeline."  
- Helpline enquirer

Everyone at Gene People is deeply grateful for the support. Together, we are Gene People.

Lastly, following the adoption of an Environmental policy which includes a public statement of our carbon emissions. Our emissions for financial year 2022-23 were 1.04 tonnes of CO<sub>2</sub>e.

**Public benefit**

The trustees confirm that they have complied with the duty in Section 17(5) of the Charities Act 2011 to have due regard to the guidance issued by the Charity Commission on public benefit. The charitable purpose for the charity within the meaning of the Act is enshrined within its objects, as given in the memorandum and articles of association, and the charitable objects are included in this report.

**FINANCIAL REVIEW**

**Reserves**

On 31 March 2023, the total monies held by Gene People stood at £10,261 of which restricted funds were £Nil. Free reserves, as defined by the Charity Commission, were £10,261. The trustees reviewed and revised the long-standing reserves policy and are of the opinion it is prudent to target approximately £25,000 in reserve. This reflects the reduction in size of the charity and provides five months of average running costs, which trustees consider to be sufficient to respond to an unexpected emergency or cover costs of an orderly wind-up should that be necessary in the future. It is a goal to achieve the target reserves figure in the next two years.

**Going concern**

The accounts show the anticipated further decline in income in 2022-23 following the restructure, therefore, the trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment using forecasts and budgets prepared to cover the period to March 2024.

In considering going concern for 2022-23, the trustees have assessed the probability of successfully raising the funding required for the reduced staffing structure. Given the support received from corporates, funders and individuals so far, the trustees have currently assessed that the charity should continue to be regarded as a going concern and therefore the financial statements include no adjustment in this respect.

**Report of the Trustees  
for the year ended 31 March 2023**

**FUTURE PLANS**

The Trustees agreed the following strategic aims for 2023-24:

- Focus on income generation through increasing visibility
- Focus on making the voice of lived experience informing strategic discussions about new treatments and reimbursement
- Continue to improve and develop the Helpline
- Hold regular webinars on a range of topics for the Partnership Network
- Hold the Gene People Leadership Symposium
- Continue to seek input from the Gene People Partnership Network Advisory Panel
- Submit responses to consultations with input from our Partnership Network where possible.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Governing document**

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

Gene People changed its name from Genetic Disorders UK (GDUK) in May 2021. The registered charity number (number 1141583) and company limited by guarantee (number 07564771) remained the same. Gene People is governed by its memorandum and articles of association dated 15 March 2011. The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

**Decision making**

The board of trustees is responsible for the overall governance, policy and strategic direction of Gene People, and have the legal responsibility for the operations of the charity and the use of resources in accordance with the objects of the charity. The trustees who have served during the year and since the year end are set out on page 1.

The charity is governed by individuals with a broad range of skills, including biotech, operations, finance and charity management expertise. A personal perspective on what it is to be part of a family affected by a genetic condition was provided by one trustee during the financial year with a trustee with lived experience of a condition joining during the period following the financial year.

**Governance and Management**

Trustees serve on the board for a period of three years that is renewable. New trustees are appointed by the serving trustees, considering the skills required by the board.

The board of trustees meets at least four times a year to review progress and policies, with additional virtual meetings via video conferencing. With the changes to the charity and the impact of the pandemic, meetings were more frequent during the year. Formal reporting by the chief executive to the trustees takes place regularly at board meetings and informally as appropriate throughout the year.

The systems of control that are designed to provide reasonable assurance against material misstatement or loss include; an annual budget approved by the trustees; regular review of financial results, budget variances and non-financial performance indicators; delegation of authority and segregation of duties; and identification and management of risks. Staff remuneration is determined according to the level of seniority and experience. New staff are offered salaries that align with the market average. As mandated by law, all staff are offered the opportunity to join the charity's pension scheme.

**Report of the Trustees  
for the year ended 31 March 2023**

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

**Risk management**

The trustees have overall responsibility for ensuring that Gene People is managing risk in a professional, responsible and constructive manner.

Trustees have considered the major risks to which the charity is exposed and have established procedures, including a risk register, to identify and manage those risks. All risks are reviewed at least twice at Board meetings during the year.

The risk register identifies the types of risks the charity may face, assessing and balancing them in terms of potential impact and likelihood of occurrence. The trustees seek to ensure that all internal controls, and in particular financial controls, comply in all respects with best practice and inter alia the guidelines issued by the Charity Commission.

The principal risks identified by trustees in the period for Gene People are:

- The charity is unable to fundraise sufficient funds and/or in a way that maintains cashflow
- Lack of investment in IT infrastructure
- Inability to meet reserves policy requirements.

Each of these key risks has a mitigation plan managed by the CEO with support from trustees.

- Covid-19 and cost of living risk

It is recognised by the Trustees that the financial performance of the charity has been and will continue to be impacted by the coronavirus (Covid-19), which was declared a global pandemic by the World Health Organisation in March 2020, and the cost of living crisis. Covid-19 is an especially constant and present challenge to many in our community, who face health issues impacted by Covid-19. The cost of living crisis is impacting how people and companies are able to support Gene People and our work.

Trustees have managed expenditure and continue to seek ways to both further manage cost whilst increasing income from a diversity of sources.

The operating environment for Gene People is the same for all charities and Trustees are cognisant of the risks this creates for the charity.

Approved by order of the board of trustees on .....13/12/2023..... and signed on its behalf by:



.....  
A J Kent - Trustee



**Independent Examiner's Report to the Trustees of  
Gene People (Registered number: 07564771)**

**Independent examiner's report to the trustees of Gene People ('the Company')**

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2023.

**Responsibilities and basis of report**

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Hazel Day BSc (Hons) FCA DChA

Tudor John Limited  
Nightingale House  
46-48 East Street  
Epsom  
Surrey  
KT17 1HQ

Date: 15th December 2023

# GENE PEOPLE

## Statement of Financial Activities for the year ended 31 March 2023

		Unrestricted fund £	Restricted funds £	2023 Total funds £	2022 Total funds £
	Notes				
<b>INCOME AND ENDOWMENTS FROM</b>					
Donations and legacies	2	<u>106,008</u>	<u>2,000</u>	<u>108,008</u>	<u>104,591</u>
<b>EXPENDITURE ON</b>					
Raising funds	3	56,492	-	56,492	76,537
<b>Charitable activities</b>	4				
Awareness and education		34,938	8,715	43,653	37,861
Relief		<u>28,702</u>	<u>-</u>	<u>28,702</u>	<u>33,802</u>
<b>Total</b>		<u>120,132</u>	<u>8,715</u>	<u>128,847</u>	<u>148,200</u>
<b>NET INCOME/(EXPENDITURE)</b>		(14,124)	(6,715)	(20,839)	(43,609)
<b>RECONCILIATION OF FUNDS</b>					
Total funds brought forward		24,385	6,715	31,100	74,709
<b>TOTAL FUNDS CARRIED FORWARD</b>		<u>10,261</u>	<u>-</u>	<u>10,261</u>	<u>31,100</u>

The notes form part of these financial statements

**GENE PEOPLE (REGISTERED NUMBER: 07564771)**

**Balance Sheet  
31 March 2023**

	Notes	Unrestricted fund £	Restricted funds £	2023 Total funds £	2022 Total funds £
<b>CURRENT ASSETS</b>					
Debtors	9	7,741	-	7,741	18,773
Cash at bank		<u>8,135</u>	<u>-</u>	<u>8,135</u>	<u>29,155</u>
		15,876	-	15,876	47,928
<b>CREDITORS</b>					
Amounts falling due within one year	10	(5,615)	-	(5,615)	(16,828)
		<u>10,261</u>	<u>-</u>	<u>10,261</u>	<u>31,100</u>
<b>NET CURRENT ASSETS</b>					
		<u>10,261</u>	<u>-</u>	<u>10,261</u>	<u>31,100</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>					
		<u>10,261</u>	<u>-</u>	<u>10,261</u>	<u>31,100</u>
<b>NET ASSETS</b>					
		<u>10,261</u>	<u>-</u>	<u>10,261</u>	<u>31,100</u>
<b>FUNDS</b>	11				
Unrestricted funds				10,261	24,385
Restricted funds				<u>-</u>	<u>6,715</u>
<b>TOTAL FUNDS</b>				<u>10,261</u>	<u>31,100</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2023 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on

.....13/12/2023..... and were signed on its behalf by:



.....  
A J Kent - Trustee

The notes form part of these financial statements

# GENE PEOPLE

## Notes to the Financial Statements for the year ended 31 March 2023

### 1. ACCOUNTING POLICIES

#### **BASIS OF PREPARING THE FINANCIAL STATEMENTS**

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

#### **CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY**

Estimates and judgements are continually evaluated and are based on historical experience and other factors including expectations of future events that are believed to be reasonable under the circumstances.

The items in the financial statements where these judgements and estimates have been made include:

- estimating the useful economic life of tangible fixed assets for the purposes of determining the annual depreciation charge;
- determining the basis for allocating support costs across expenditure classifications

#### **INCOME**

Income is recognised in the period in which the charity has entitlement to the income and the amount can be measured reliably and it is probable that the income will be received. Income is deferred only when the charity has to fulfil conditions before becoming entitled to it or where the donor or funder has specified that the income is to be expended in a future accounting period. Income comprises donations, legacies, grants in respect of core funding, income from the main charitable activity, Jeans for Genes, merchandise sales and interest receivable.

Donations and grants in respect of charitable activities are recognised when the charity has confirmation of both the amount and settlement date. In the event of amounts pledged but not received, the amount is accrued for where the receipt is considered probable. In the event that a donation or grant subject to conditions that require a level of performance before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met or the fulfilment of those conditions is wholly within the control of the charity and it is probable that those conditions will be fulfilled in the reporting period.

Legacies are included in the statement of financial activities when the charity is entitled to the legacy, the executors have established that there are sufficient surplus assets in the estate to pay the legacy and any conditions attached to the legacy are within the control of the charity.

Entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted; the estate has been finalised and notification has been made by the executor to the charity that a distribution will be made; when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution.

Where legacies have been notified to the charity or the charity is aware of the granting of probate, but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material. In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title of the asset having been transferred to the charity.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

#### **EXPENDITURE**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

## **GENE PEOPLE**

### **Notes to the Financial Statements - continued for the year ended 31 March 2023**

#### **1. ACCOUNTING POLICIES - continued**

##### **EXPENDITURE**

Expenditure is accounted for on an accruals basis, exclusive of any VAT which is recoverable. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs, which contribute to more than one activity, and support costs, which are not attributable to a single activity, are apportioned between those activities on a basis consistent with the use of resources.

Governance costs include the costs incurred in the governance of the charity and are primarily associated with constitutional and statutory requirements.

Expenditure is only deferred when it relates to future years.

Grants awarded are recognised when the offer and amount of the grant is conveyed to the beneficiary. Grants are paid in furtherance of the charitable objective of the charity.

All expenditure is inclusive of irrecoverable VAT.

##### **RELATED PARTY EXEMPTION**

The charitable company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

##### **TAXATION**

The charity is exempt from corporation tax on its charitable activities.

##### **FUND ACCOUNTING**

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. The costs of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

##### **GOING CONCERN**

The accounts show slight increase in revenue in 2022-23, the trustees have assessed that the use of going concern is appropriate in preparing these financial statements. The trustees have made this assessment using forecasts and budgets prepared to cover period to March 2024.

In considering going concern for 2023-24, the trustees have assessed the profitability of successfully raising the necessary funding through the fundraising strategy and agreed that reserves could be used in this quasi-start-up phase for the reformed charity. Given the support received from corporates, funders and individuals so far, the trustees have assessed that charity should not be so affected by the changes that it should not be regarded as a going concern and therefore the financial statements include no adjustment in this respect.

##### **BASIS OF CONSOLIDATION**

The Statement of financial activities (SoFA) and balance sheet consolidated the financial statements of the charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis. No separate SoFA has been presented for the charity alone as permitted by section 408 of the Companies Act 2006.

##### **FINANCIAL INSTRUMENTS**

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans, which are subsequently measured at amortised cost using the effective interest method.

# **GENE PEOPLE**

## **Notes to the Financial Statements - continued for the year ended 31 March 2023**

### **2. DONATIONS AND LEGACIES**

	2023	2022
	£	£
Donations	<u>108,008</u>	<u>104,591</u>

### **3. RAISING FUNDS**

#### **OTHER TRADING ACTIVITIES**

	2023	2022
	£	£
Staff costs	39,236	62,072
Promotional items	<u>17,256</u>	<u>14,465</u>
	<u>56,492</u>	<u>76,537</u>

### **4. CHARITABLE ACTIVITIES COSTS**

	Direct Costs £	Support costs (see note 5) £	Totals £
Awareness and education	8,983	34,670	43,653
Relief	<u>-</u>	<u>28,702</u>	<u>28,702</u>
	<u>8,983</u>	<u>63,372</u>	<u>72,355</u>

### **5. SUPPORT COSTS**

	Management £	Governance costs £	Totals £
Awareness and education	26,915	7,755	34,670
Relief	<u>28,702</u>	<u>-</u>	<u>28,702</u>
	<u>55,617</u>	<u>7,755</u>	<u>63,372</u>

### **6. TRUSTEES' REMUNERATION AND BENEFITS**

There were no trustees' remuneration or other benefits for the year ended 31 March 2023 nor for the year ended 31 March 2022.

#### **TRUSTEES' EXPENSES**

There were no trustees' expenses paid for the year ended 31 March 2023 nor for the year ended 31 March 2022.

# **GENE PEOPLE**

## **Notes to the Financial Statements - continued for the year ended 31 March 2023**

### **7. STAFF COSTS**

Staff costs were as follows:

	2023	2022
	£	£
Wages and salaries	84,567	105,056
Social security costs	4,367	5,784
Other pension costs	<u>5,920</u>	<u>6,976</u>
	<u><u>94,854</u></u>	<u><u>117,815</u></u>

The average monthly number of employees during the year was as follows:

	2023	2022
Fundraising	1	1
Charitable	<u>1</u>	<u>2</u>
	<u><u>2</u></u>	<u><u>3</u></u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2023	2022
£60,001 - £70,000	<u>1</u>	<u>1</u>

The aggregate employee benefits paid to key management personnel were £69,015 (2022: £65,890).

### **8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES**

	Unrestricted fund £	Restricted funds £	Total funds £
<b>INCOME AND ENDOWMENTS FROM</b>			
Donations and legacies	<u>94,591</u>	<u>10,000</u>	<u>104,591</u>
<b>EXPENDITURE ON</b>			
Raising funds	76,537	-	76,537
<b>Charitable activities</b>			
Awareness and education	18,861	19,000	37,861
Relief	<u>33,802</u>	<u>-</u>	<u>33,802</u>
<b>Total</b>	<u><u>129,200</u></u>	<u><u>19,000</u></u>	<u><u>148,200</u></u>
<b>NET INCOME/(EXPENDITURE)</b>	(34,609)	(9,000)	(43,609)
<b>RECONCILIATION OF FUNDS</b>			
Total funds brought forward	<u>58,994</u>	<u>15,715</u>	<u>74,709</u>
<b>TOTAL FUNDS CARRIED FORWARD</b>	<u><u>24,385</u></u>	<u><u>6,715</u></u>	<u><u>31,100</u></u>

**GENE PEOPLE**

**Notes to the Financial Statements - continued  
for the year ended 31 March 2023**

**9. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2023	2022
	£	£
Trade debtors	-	10,185
Other debtors	11	11
VAT	6,252	6,252
Prepayments and accrued income	<u>1,478</u>	<u>2,325</u>
	<u>7,741</u>	<u>18,773</u>

**10. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	2023	2022
	£	£
Trade creditors	735	1,181
Social security and other taxes	1,709	3,057
Other creditors	201	9,530
Accruals and deferred income	<u>2,970</u>	<u>3,060</u>
	<u>5,615</u>	<u>16,828</u>

**11. MOVEMENT IN FUNDS**

	At 1.4.22	Net movement in funds	At 31.3.23
	£	£	£
<b>Unrestricted funds</b>			
General fund	24,385	(14,124)	10,261
<b>Restricted funds</b>			
Roald Dahl's MCC	<u>6,715</u>	<u>(6,715)</u>	<u>-</u>
<b>TOTAL FUNDS</b>	<u>31,100</u>	<u>(20,839)</u>	<u>10,261</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
<b>Unrestricted funds</b>			
General fund	106,008	(120,132)	(14,124)
<b>Restricted funds</b>			
Symposium	2,000	(2,000)	-
Roald Dahl's MCC	<u>-</u>	<u>(6,715)</u>	<u>(6,715)</u>
	<u>2,000</u>	<u>(8,715)</u>	<u>(6,715)</u>
<b>TOTAL FUNDS</b>	<u>108,008</u>	<u>(128,847)</u>	<u>(20,839)</u>



# GENE PEOPLE

## Notes to the Financial Statements - continued for the year ended 31 March 2023

### 11. MOVEMENT IN FUNDS - continued

#### Comparatives for movement in funds

	At 1.4.21 £	Net movement in funds £	At 31.3.22 £
<b>Unrestricted funds</b>			
General fund	58,994	(34,609)	24,385
<b>Restricted funds</b>			
Roald Dahl's MCC	6,715	-	6,715
GDUK Helpline	<u>9,000</u>	<u>(9,000)</u>	<u>-</u>
	<u>15,715</u>	<u>(9,000)</u>	<u>6,715</u>
<b>TOTAL FUNDS</b>	<u><u>74,709</u></u>	<u><u>(43,609)</u></u>	<u><u>31,100</u></u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
<b>Unrestricted funds</b>			
General fund	94,591	(129,200)	(34,609)
<b>Restricted funds</b>			
GDUK Helpline	<u>10,000</u>	<u>(19,000)</u>	<u>(9,000)</u>
<b>TOTAL FUNDS</b>	<u><u>104,591</u></u>	<u><u>(148,200)</u></u>	<u><u>(43,609)</u></u>

### 12. EMPLOYEE BENEFIT OBLIGATIONS

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in independently administered funds. The pension costs charge represents contributions payable by the group to the funds and amounted to £5,920 (2022: £6,976). Contributions totalling £272 (2022: £835) were payable to the funds at the year end and are included in creditors. The expense and liability have been recognised in unrestricted funds.

### 13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 March 2023.

## **GENE PEOPLE**

### **Notes to the Financial Statements - continued for the year ended 31 March 2023**

#### **14. COMPANY STATUS**

The charity is a private company limited by guarantee. The members of the company are the trustees named on page 1. In the event of the charity being wound up the liability in respect of the guarantee is limited to £1 per member of the charity.